{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T23:55:46Z","timestamp":1783814146142,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009553","name":"Agentura Pro Zdravotnick\u00fd V\u00fdzkum \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["NV19-01-00435"],"award-info":[{"award-number":["NV19-01-00435"]}],"id":[{"id":"10.13039\/501100009553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009553","name":"Agentura Pro Zdravotnick\u00fd V\u00fdzkum \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["NV19-01-00435"],"award-info":[{"award-number":["NV19-01-00435"]}],"id":[{"id":"10.13039\/501100009553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014911","name":"Ministerstvo Obrany \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["MO 1012"],"award-info":[{"award-number":["MO 1012"]}],"id":[{"id":"10.13039\/501100014911","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014911","name":"Ministerstvo Obrany \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["MO 1012"],"award-info":[{"award-number":["MO 1012"]}],"id":[{"id":"10.13039\/501100014911","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014911","name":"Ministerstvo Obrany \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["MO 1012"],"award-info":[{"award-number":["MO 1012"]}],"id":[{"id":"10.13039\/501100014911","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Progres 25"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hormone-secreting adenomas are treated in many neurosurgical centers within Europe. The goal of the survey is to understand variance in practice management of pituitary tumors amongst neurosurgical centers. A list of departments performing pituitary surgery was created. The survey consisted of 58 questions. This study focuses on neurosurgical care of hormone-secreting adenomas. For analysis, the departments were divided into four subgroups: academic\/non-academic, high-volume\/low-volume, \u201cmainly endoscopic\/mainly microscopic practice\u201d and geographical regions. Data from 254 departments from 34 countries were obtained. Most centers surgically treat 1\u20135 hormone-secreting adenomas per year. In prolactinomas this is the case in 194 centers, (76.4%), in GH-secreting adenomas: 133 centers, (52.4%), ACTH-secreting adenomas: 172 centers, (69.8%). Surgery as a primary treatment of prolactinomas is considered in 64 centers (25.2%). In 47 centers (18.8%), GH-secreting microadenomas are often treated pharmacologically first. Debulking surgery for an invasive GH-secreting adenoma in which hormonal remission is not a realistic goal of the surgery and the patient has no visual deficit surgery is always or mostly indicated in 156 centers (62.9%). Routine postoperative hydrocortisone replacement therapy is administered in 147 centers (58.6%). Our survey shows that in most centers, few hormone-secreting adenomas are treated per year. In about 25% of the centers, prolactinoma surgery may be regarded as first-line treatment; in about 20% of the centers, medical treatment is the first-line treatment for GH-secreting adenomas. Pretreatment for ACTH-secreting adenomas is routinely used in 21% of centers. This survey may serve as plea for neurosurgical care centralization of hormone-secreting adenomas.<\/jats:p>","DOI":"10.1038\/s41598-022-10300-1","type":"journal-article","created":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T19:03:16Z","timestamp":1650481396000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Endocrinological aspects of pituitary adenoma surgery in Europe"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8609-4789","authenticated-orcid":false,"given":"David","family":"Netuka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Grotenhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Foroglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Zenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Froehlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Ringel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Sampron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Komarc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikul\u00e1\u0161","family":"Kos\u00e1k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"M\u00e1jovsk\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,20]]},"reference":[{"key":"10300_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s10143-021-01614-1","author":"M Majovsky","year":"2021","unstructured":"Majovsky, M. et al. What is the current clinical practice in pituitary adenoma surgery in Europe? European pituitary adenoma surgery survey (EU-PASS) results: technical part. Neurosurg. Rev. https:\/\/doi.org\/10.1007\/s10143-021-01614-1 (2021).","journal-title":"Neurosurg. Rev."},{"key":"10300_CR2","doi-asserted-by":"crossref","unstructured":"Netuka, D., Grotenhuis, A., Foroglou, N., Zenga, F., Froehlich, S., Ringel, F., Sampron, N., Thomas, N., Komarc, M., & M\u00e1jovsk\u00fd, M. The European pituitary adenoma surgery survey: neurosurgical centers and non-functioning adenomas. Eur. J. Endocrinol. (2021)","DOI":"10.1016\/j.bas.2022.101541"},{"key":"10300_CR3","doi-asserted-by":"publisher","first-page":"4709","DOI":"10.1210\/jc.2003-030461","volume":"88","author":"FG Barker","year":"2003","unstructured":"Barker, F. G., Klibanski, A. & Swearingen, B. Transsphenoidal surgery for pituitary tumors in the United States, 1996\u20132000: mortality, morbidity, and the effects of hospital and surgeon volume. J. Clin. Endocrinol. Metab. 88, 4709\u20134719 (2003).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10300_CR4","unstructured":"United Nations Statistics Division\u2013Geographic Regions (1999)"},{"key":"10300_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-017-0838-2","author":"FF Casanueva","year":"2017","unstructured":"Casanueva, F. F. et al. On behalf of the pituitary society: expert group on pituitary tumors: criteria for the definition of pituitary tumor centers of excellence (PTCOE): a pituitary society statement. Pituitary https:\/\/doi.org\/10.1007\/s11102-017-0838-2 (2017).","journal-title":"Pituitary"},{"key":"10300_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ensci.2021.100317","author":"G Kasper","year":"2021","unstructured":"Kasper, G., Samuel, N., Alkins, R. & Khan, O. H. Practice patterns in the management of recurrent and residual non-functioning pituitary adenomas: results from a Canada-wide survey. eNeurologicalScience https:\/\/doi.org\/10.1016\/j.ensci.2021.100317 (2021).","journal-title":"eNeurologicalScience"},{"key":"10300_CR7","doi-asserted-by":"publisher","unstructured":"Zamanipoor Najafabadi, A.H., Zandbergen, I.M., de Vries, F., Broersen, L.H., van den Akker-van Marle, M.E., Pereira, A.M., Peul, W.C., Dekkers, O.M., van Furth, W.R., Biermasz, N.R.: Surgery as a viable alternative first-line treatment for prolactinoma patients. a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. (2020). doi:https:\/\/doi.org\/10.1210\/clinem\/dgz144","DOI":"10.1210\/clinem\/dgz144"},{"key":"10300_CR8","doi-asserted-by":"publisher","DOI":"10.3171\/2017.2.JNS1784","author":"MJ Rutkowski","year":"2018","unstructured":"Rutkowski, M. J., Kunwar, S., Blevins, L. & Aghi, M. K. Surgical intervention for pituitary apoplexy: an analysis of functional outcomes. J. Neurosurg. https:\/\/doi.org\/10.3171\/2017.2.JNS1784 (2018).","journal-title":"J. Neurosurg."},{"key":"10300_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.surneu.2004.03.014","author":"D Agrawal","year":"2005","unstructured":"Agrawal, D. & Mahapatra, A. K. Visual outcome of blind eyes in pituitary apoplexy after transsphenoidal surgery: a series of 14 eyes. Surg. Neurol. https:\/\/doi.org\/10.1016\/j.surneu.2004.03.014 (2005).","journal-title":"Surg. Neurol."},{"key":"10300_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-020-09588-z","author":"A Giustina","year":"2020","unstructured":"Giustina, A. et al. Multidisciplinary management of acromegaly: a consensus. Rev. Endocr. Metab. Disord. https:\/\/doi.org\/10.1007\/s11154-020-09588-z (2020).","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10300_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-015-0853-x","author":"M Losa","year":"2016","unstructured":"Losa, M. & Bollerslev, J. Pros and cons in endocrine practice: pre-surgical treatment with somatostatin analogues in acromegaly. Endocrine https:\/\/doi.org\/10.1007\/s12020-015-0853-x (2016).","journal-title":"Endocrine"},{"key":"10300_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-019-00952-0","author":"M Losa","year":"2019","unstructured":"Losa, M., Donofrio, C. A., Gemma, M., Barzaghi, L. R. & Mortini, P. Pretreatment with somatostatin analogs does not affect the anesthesiologic management of patients with acromegaly. Pituitary https:\/\/doi.org\/10.1007\/s11102-019-00952-0 (2019).","journal-title":"Pituitary"},{"key":"10300_CR13","doi-asserted-by":"publisher","DOI":"10.1530\/EC-20-0414","author":"M Araujo-Castro","year":"2021","unstructured":"Araujo-Castro, M. et al. Presurgical somatostatin receptor ligand treatment does not affect tumor consistency in GH-secreting pituitary macroadenomas. Endocr. Connect. https:\/\/doi.org\/10.1530\/EC-20-0414 (2021).","journal-title":"Endocr. Connect."},{"key":"10300_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-018-0916-0","author":"F Albarel","year":"2018","unstructured":"Albarel, F. et al. Brue, T: Pre-surgical medical treatment, a major prognostic factor for long-term remission in acromegaly. Pituitary https:\/\/doi.org\/10.1007\/s11102-018-0916-0 (2018).","journal-title":"Pituitary"},{"key":"10300_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2018.02.006","author":"L Lv","year":"2018","unstructured":"Lv, L. et al. Presurgical treatment with somatostatin analogues in growth hormone-secreting pituitary adenomas: a long-term single-center experience. Clin. Neurol. Neurosurg. https:\/\/doi.org\/10.1016\/j.clineuro.2018.02.006 (2018).","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10300_CR16","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-3318","author":"PJ Caron","year":"2014","unstructured":"Caron, P. J. et al. PRIMARYS investigators: tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J. Clin. Endocrinol. Metab. https:\/\/doi.org\/10.1210\/jc.2013-3318 (2014).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10300_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-015-0677-y","author":"A Colao","year":"2016","unstructured":"Colao, A., Auriemma, R. S. & Pivonello, R. The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly. Pituitary https:\/\/doi.org\/10.1007\/s11102-015-0677-y (2016).","journal-title":"Pituitary"},{"key":"10300_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2016.02.003","author":"JS Chang","year":"2016","unstructured":"Chang, J. S., Tseng, H. M. & Chang, T. C. Serial follow-up of presurgical treatment using pasireotide long-acting release with or without octreotide long-acting release for na\u00efve active acromegaly. J. Formos. Med. Assoc. https:\/\/doi.org\/10.1016\/j.jfma.2016.02.003 (2016).","journal-title":"J. Formos. Med. Assoc."},{"key":"10300_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-015-0601-2","author":"S Cannavo","year":"2016","unstructured":"Cannavo, S. et al. Clinical management of critically ill patients with Cushing\u2019s disease due to ACTH-secreting pituitary macroadenomas: effectiveness of presurgical treatment with pasireotide. Endocrine https:\/\/doi.org\/10.1007\/s12020-015-0601-2 (2016).","journal-title":"Endocrine"},{"key":"10300_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12286","author":"OF van den Bosch","year":"2014","unstructured":"van den Bosch, O. F., Stades, A. M. & Zelissen, P. M. Increased long-term remission after adequate medical cortisol suppression therapy as presurgical treatment in Cushing\u2019s disease. Clin. Endocrinol. https:\/\/doi.org\/10.1111\/cen.12286 (2014).","journal-title":"Clin. Endocrinol."},{"key":"10300_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-012-0455-z","author":"N Hameed","year":"2013","unstructured":"Hameed, N. et al. Remission rate after transsphenoidal surgery in patients with pathologically confirmed Cushing\u2019s disease, the role of cortisol, ACTH assessment and immediate reoperation: a large single center experience. Pituitary https:\/\/doi.org\/10.1007\/s11102-012-0455-z (2013).","journal-title":"Pituitary"},{"key":"10300_CR22","doi-asserted-by":"publisher","DOI":"10.3171\/2017.6.JNS17635","author":"M Mayberg","year":"2018","unstructured":"Mayberg, M. et al. Dynamics of postoperative serum cortisol after transsphenoidal surgery for Cushing\u2019s disease: implications for immediate reoperation and remission. J. Neurosurg. https:\/\/doi.org\/10.3171\/2017.6.JNS17635 (2018).","journal-title":"J. Neurosurg."},{"key":"10300_CR23","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-0456","author":"JR Lindsay","year":"2011","unstructured":"Lindsay, J. R., Oldfield, E. H., Stratakis, C. A. & Nieman, L. K. The postoperative basal cortisol and CRH tests for prediction of long-term remission from Cushing\u2019s disease after transsphenoidal surgery. J. Clin. Endocrinol. Metab. https:\/\/doi.org\/10.1210\/jc.2011-0456 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10300_CR24","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1055\/s-2007-980192","volume":"39","author":"TC Friedman","year":"2007","unstructured":"Friedman, T. C., Zuckerbraun, E. & Lee, M. L. Dynamic pituitary MRI has high sensitivity and specificity for the diagnosis of mild Cushing\u2019s syndrome and should be part of the initial workup. Horm. Metab. Res. 39, 451\u2013456 (2007).","journal-title":"Horm. Metab. Res."},{"key":"10300_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-71628-0","author":"Z Liu","year":"2020","unstructured":"Liu, Z. et al. High positive predictive value of the combined pituitary dynamic enhanced MRI and high-dose dexamethasone suppression tests in the diagnosis of Cushing\u2019s disease bypassing bilateral inferior petrosal sinus sampling. Sci. Rep. https:\/\/doi.org\/10.1038\/s41598-020-71628-0 (2020).","journal-title":"Sci. Rep."},{"key":"10300_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-015-3809-x","author":"AAJ de Rotte","year":"2016","unstructured":"de Rotte, A. A. J. et al. High resolution pituitary gland MRI at 7.0 tesla: a clinical evaluation in Cushing\u2019s disease. Eur. Radiol. https:\/\/doi.org\/10.1007\/s00330-015-3809-x (2016).","journal-title":"Eur. Radiol."},{"key":"10300_CR27","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20180492","author":"G Barisano","year":"2019","unstructured":"Barisano, G. et al. Clinical 7 T MRI: are we there yet? A review about magnetic resonance imaging at ultra-high field. Br. J. Radiol. https:\/\/doi.org\/10.1259\/bjr.20180492 (2019).","journal-title":"Br. J. Radiol."},{"key":"10300_CR28","doi-asserted-by":"publisher","first-page":"5593","DOI":"10.1210\/jc.2003-030871","volume":"88","author":"G Arnaldi","year":"2003","unstructured":"Arnaldi, G., Angeli, A. & Atkinson, A. B. Diagnosis and complications of Cushing\u2019s syndrome: a consensus statement. J. Clin. Endocrinol. Metab. 88, 5593\u20135602 (2003).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10300_CR29","doi-asserted-by":"publisher","unstructured":"Tortora, F., Negro, A., Briganti, F., Del Basso De Caro, M.L., Cavallo, L.M., Solari, D., Somma T., Brunese, L., Caranci, F. Pituitary magnetic resonance imaging vs. bilateral inferior petrosal sinus sampling: comparison between non-invasive and invasive diagnostic techniques for Cushing's disease-a narrative review. Gland Surg. (2020). doi:https:\/\/doi.org\/10.21037\/gs-20-654","DOI":"10.21037\/gs-20-654"},{"key":"10300_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-020-00623-3","author":"H Wang","year":"2020","unstructured":"Wang, H., Ba, Y., Xing, Q. & Cai, R. C. Differential diagnostic value of bilateral inferior Petrosal sinus sampling (BIPSS) in ACTH-dependent cushing syndrome: a systematic review and Meta-analysis. BMC Endocr. Disord. https:\/\/doi.org\/10.1186\/s12902-020-00623-3 (2020).","journal-title":"BMC Endocr. Disord."},{"key":"10300_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0119621","author":"M Tohti","year":"2015","unstructured":"Tohti, M. et al. Is peri-operative steroid replacement therapy necessary for the pituitary adenomas treated with surgery? A systematic review and meta analysis. PLoS ONE https:\/\/doi.org\/10.1371\/journal.pone.0119621 (2015).","journal-title":"PLoS ONE"},{"key":"10300_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s00701-019-03885-6","author":"O Fridman-Bengtsson","year":"2019","unstructured":"Fridman-Bengtsson, O. et al. Evaluation of different hydrocortisone treatment strategies in transsphenoidal pituitary surgery. Acta Neurochir. https:\/\/doi.org\/10.1007\/s00701-019-03885-6 (2019).","journal-title":"Acta Neurochir."},{"key":"10300_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s00701-012-1474-2","author":"C De Tommasi","year":"2012","unstructured":"De Tommasi, C., Goguen, J. & Cusimano, M. D. Transphenoidal surgery without steroid replacement in patients with morning serum cortisol below 9 \u03bcg\/dl (250 Nmol\/l). Acta Neuroschir. https:\/\/doi.org\/10.1007\/s00701-012-1474-2 (2012).","journal-title":"Acta Neuroschir."},{"key":"10300_CR34","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.6.8547","author":"WJ Inder","year":"2002","unstructured":"Inder, W. J. & Hunt, P. J. Glucocorticoid replacement in pituitary surgery: guidelines for perioperative assessment and management. J. Clin. Endocrinol. Metab. https:\/\/doi.org\/10.1210\/jcem.87.6.8547 (2002).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10300_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2007.02995.x","author":"JM Wentworth","year":"2008","unstructured":"Wentworth, J. M. et al. Prospective evaluation of a protocol for reduced glucocorticoid replacement in transsphenoidal pituitary adenomectomy: prophylactic glucocorticoid replacement is seldom necessary. Clin. Endocrinol. https:\/\/doi.org\/10.1111\/j.1365-2265.2007.02995.x (2008).","journal-title":"Clin. Endocrinol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10300-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10300-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10300-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T02:07:07Z","timestamp":1669342027000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10300-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,20]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10300"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-10300-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,20]]},"assertion":[{"value":"14 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6529"}}